Loading clinical trials...
Loading clinical trials...
Browse 3,379 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.
Find trials near:
Showing 461-480 of 3,379 trials
NCT06744075
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently recommended examination, which is Positon Emission Tomography (PET-CT) imaging at the end of first-line treatment (assessment of therapeutic response using the Deauville score according to the Lugano 2014 criteria). The study will focus on demonstrating the ability of ctDNA clearance to predict 1-year and 2-year outcomes (lymphoma progression or death) in patients treated with first-line therapy for B-cell lymphoma or Hodgkin lymphoma. This could contribute to establishing minimal residual disease clearance as a key endpoint for evaluating the efficacy of therapeutic strategies in future clinical trials and guiding patient management (e.g., de-escalation or intensification strategies, redirection toward immunotherapy, and theranostic approaches).
NCT07310186
Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.